Board of Directors

Peter Høngaard Andersen

Chairman of the Board, Scandion Oncology.

Holds a degree in Chemistry, Biochemistry and medicine.
Extensive drug discovery and development experience from Novo Nordisk and Lundbeck latest as EVP and Head of Research and corporate patents.
Founder of Innovation Fund Denmark and Managing Director until May 2019 and chairing Innovative Medicines Initiative (IMI) from 2009 – 2014.
Co-founder of e.g. Acadia Pharmaceuticals, Zealand Pharma, Glycom, Epitherapeutics, Prexton Therapeutics.


Jørgen Bardenfleth

Vice-Chairman of the Board, Scandion Oncology.
Chairman of the Board, Lyngsoe Systems, Dubex and Symbion.
Boardmember in EG, Accelerace, Prodata Consult, BLOXHUB (vice chair), et al.
Steering Committee Chairman in Copenhagen Healthtech Cluster and Innofounder.

Carl Borrebäck

D.Sc, PhD.
Professor Lund University.
Co-founder of Immnovia AB, Senzagen AB, BioInvent International AB, Alligator BioScience AB.

Christian Vinding Thomsen

Partner, Bech-Bruun Law Firm.
Life Science specialist (M&A and regulatory).
Professional board member.

Thomas Feldthus

CEO of Fertilizer Invest ApS (M.Sc., MBA).
Previously, vVD, CFO and co-founder of Saniona and also CFO and co-founder of Symphogen A/S.

Bo Rode Hansen

President and CEO of Genevant Sciences Inc. (MSc, Ph.D., MBA).
Previously, Global Head of Roche RNA Therapeutics, General Manager of Roche Innovation Center Copenhagen and Head of Drug Discovery & Alliance at Santaris (acquired by Roche).

Annie Rasmussen

Employee elected.

Registered Nurse, Special Diploma.
Extensive Oncology Clinical Research & Operational experience from Oncology Clinics & Research Units, Smithkline Beecham and Biotech Companies since 1982. Former President of the Danish Oncology Nursing Society, Previous Co-founder & CCO of Topotarget A/S & EVP Clinical Operation Oncology Venture A/S. Founder of HealthCreationDK and CancerGuidesDK. Board Member of North Star Group A/S. CCO & Member of the Management Team in Scandion Oncology A/S.


Scandion Oncology has two promising compounds in the pipeline, including SCO-101, which has completed four Phase I trials, and SCO-201, which is in preclinical testing stages. We aim to conclude one Phase II trial within the next 2 years. Upon conclusion of the Phase II trial, we will be ready to consider exit or partner options.

Clinical Trials

Our lead compound – SCO-101 – has been shown to enhance the effect of certain standard chemotherapy when given in combination. We are planning two Phase II trials within metastatic colorectal cancer and metastatic breast cancer. We are simultaneously developing SCO-201, which will target other solid tumors.


Detailed analyses suggests the market for Scandion Oncology’s products to be more than EUR 4 billion annually. We believe our patents could be attractive for larger pharmaceutical companies to combine with their existing cancer treatments.

Co-funded by the Horizon 2020 programme of the European Union
Co-funded by the COSME programme of the European Union